ClinicalTrials.gg
Not yet recruitingNCT07783672Updated Aug 25, 2026

Prospective Randomized Study of TPS + CBT VS TPS Alone: Readmission, Opioid Use, and Chronic Pain

An interventional study of Transitional Pain Service in Pain, sponsored by M.D. Anderson Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies in Pain by M.D. Anderson Cancer Center — 5 open to participants now, 9 under way, none of them phase 3. Pain · M.D. Anderson Cancer Center.

Planned enrollment
Largest of 19
400 · median 27
Started
2027
with 1 other
No phase
11 of 27
4 open now
Registered
26th of 27
by date

Among the 27 studies in Pain by M.D. Anderson Cancer Center, this one has the largest planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2027, is one of 11 with no phase, and was the 26th registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 27 studies in Pain by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Pain by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This study aims to evaluate the impact of a Transitional Pain Service (TPS) on hospital readmission rates, opioid consumption, and chronic post-surgical pain(CPSP), Despite increasing recognition of the benefits of integrated transitional pain care, there are limited prospective data evaluating its impact on 30-day readmissions, longitudinal opioid use, and CPSP. This protocol will systematically collect prospective patient data to assess these outcomes.

Read the detailed description

Primary Objective:

To compare the 30-day hospital readmission rate in patients seen by to the Transitional Pain Service.

Secondary Objectives:

  1. To evaluate reduction in opioid use (MME) at 30, 60, 90, 180, and 365 days.
  2. To evaluate patient reported outcomes using BPI, CAGE-AID, SOAPP-14, ESAS, PROMIS-29 at 30, 60, 90, 180, and 365 days to assess patient-reported quality of life and pain outcomes longitudinally.
  3. To evaluate the incidence of CPSP
  4. To assess demographic and clinical predictors of readmission and opioid reduction.
  5. Compare outcomes between TPS patients who receive a brief, skills-based mini-CBT group intervention vs. TPS patients who do not receive mini-CBT, including:

    • Time trends across 30, 60, 90 days, and 6 and 12 months.
    • Opioid use (daily MME), and proportion achieving ≥30% MME reduction from baseline;
    • Pain intensity (NRS/10), BPI severity \& interference, PROMIS-29 domains;
    • beyond 30-day hospital readmission rate
03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Chronic pain syndrome Patients with a h/o or current substance use Patients on a daily opioid dose (morphine equivalency) of ≥90 Consulted for transitional pain service

Exclusion criteria

Exclusion Criteria:

Not seen by transitional pain service

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    CBT: TPS Patients Receiving Mini-CBT

    Participants consulted to TPS will be prospectively enrolled.

    Behavioral: Transitional Pain Service

  • Experimental
    No-CBT: TPS Patients Not Receiving Mini-CBT

    Participants consulted to TPS will be prospectively enrolled.

    Behavioral: Transitional Pain Service

Interventions

  • BehavioralTransitional Pain Service

    Participants will receive a brief, skills-based mini-CBT group intervention

06

What researchers measure

Primary outcomes

  1. Safety and Adverse Events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Time frame: Through study completion; an average of 1 year.

07

Study locations

1 site
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for May 2029, 27 months later.

Of 3,746 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 27 months is above that.

Counting every sponsor, half of 3,845 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2026
First posted
Aug 25, 2026
StartEst.
Feb 1, 2027
Primary completionEst.
May 1, 2029
CompletionEst.
May 1, 2031
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07783672
Responsible party
Sponsor
First posted
Aug 25, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
May 1, 2029 (estimated)
Completion
May 1, 2031 (estimated)
Last update
Aug 25, 2026

Study contacts

Lakshmi Koyyalagunta, MD
Contact
dkoyyala@mdanderson.org
(713) 745-4939
Lakshmi Koyyalagunta, MD
principal investigator · UT MD Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion